Genmab's GEN1160 Clinical Study: A Promising New Cancer Treatment

Genmab announced an update on its ongoing clinical study for GEN1160, a CD70 targeted antibody-drug conjugate for metastatic RCC, NPC, and NHL. The Phase 1/2 study aims to evaluate safety and efficacy, with a focus on optimal dosing and treatment outcomes. The study began on March 15, 2023, and is expected to complete in August 2025. A successful outcome could positively influence Genmab's stock performance and bolster investor sentiment in the competitive oncology market.